Phase
Condition
Cancer/tumors
Multiple Myeloma
Lymphoproliferative Disorders
Treatment
Idecabtagene vicleucel
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Adult participants ≥19 years of age
Korean participants with newly diagnosed multiple myeloma who had a suboptimalresponse after autologous stem cell transplantation (ASCT) and who were treated withidecabtagene vicleucel (assigned to Arm A) in the KarMMa-9 trial (CA089-1043)
Participants must understand and voluntarily sign and informed consent form (ICF)for the Korea long-term follow-up surveillance study prior to anysurveillance-related procedures being conducted
Exclusion
Exclusion Criteria:
Participants who participate in KarMMa-9 trial (CA089-1043) but disagree withlong-term follow-up surveillance in Korea
Participants who are not possible to treat with Ide-cel within 9 dayspost-completion of lymphodepleting chemotherapy (LDC), if delays occur. However,depending on the participants recovery status, whether idecabtagene vicleucel isadministered or not, should be discussed with a medical monitor
Study Design
Connect with a study center
Chonnam National University Hwasun Hospital
Hwasun, Jeonranamdo 58128
Korea, Republic ofActive - Recruiting
Asan Medical Center
Seoul, Seoul-teukbyeolsi [Seoul] 05505
Korea, Republic ofActive - Recruiting
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [Seoul] 06351
Korea, Republic ofActive - Recruiting
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [Seoul] 03080
Korea, Republic ofActive - Recruiting
The Catholic Univ. of Korea Seoul St. Mary's Hospital
Seoul, Seoul-teukbyeolsi [Seoul] 06591
Korea, Republic ofActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.